home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  December 22, 2024
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries

USDNA, Inc.

PO Box 33101
Reno
United States of America, Nevada

Phone: 7078002025
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.

Description:

USDNA, Inc is a US biotechnology company specialized in providing high quality Thermostable DNA Polymerases and Reagents for the biotechnology field. US DNA integrates worldwide expertise to offer its clients world-class technology with US reliability and support.

USDNA provides biotech products with a unique combination of high quality, ease of use/storage, familiarity, consistency and great value. At USDNA, we know our clients can not afford to risk problems created by communication or logistics.  With USDNA, you know you are secure with a US provider specialized in international business and southern hospitality.

USDNA offers independent and large users wholesale prices for the latest technology in Thermostable DNA Polymerases and Reagents. Get on board with the Who's Who of the biotech clients including leading publically traded companies, government agencies, top universties, and independent companies using the top quality at low prices to leverage your resources.

USDNA also offers our clients FREE strategic planning consulting services in the spirit of, "When you succeed, we succeed." Past client projects include: A strategic business plan that raised $32 million on NASDAQ in late-stage funding; International expansion plan to include product line and vertical strategy; Competitive edge market penetration to expand from a narrow-market biotech platform company to a competitive services and vertical market company with minimal capital expenditure; Supply chain reorganization to reduce downtime, create a Just In Time pre-load plan that saved 20% by reducing productivity losses; Increased productivity ("USDNA allowed us to go from 1 million samples in 2.5 hours to 1 billion in 3 hours due to its durability!" - statement by a Lab Director subsequently promoted to Division Director and the Division Director promoted to VP of Corporate Development.

Contact us today to receive your catalog and price list.



Selected Categories:
Product Company   Service Company
Biopharma
- General
Biotech
- General
Diagnostics
- General
Pharmaceutical
- General
Supplier
- General
Consulting
- Strategic

Last update of this entry: September 19, 2019

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.